Verdad Advisers’s Kalaris Therapeutics KLRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$405K Buy
140,232
+59,935
+75% +$232K 0.43% 84
2026
Q2
$327K Buy
+80,297
New +$417K 0.31% 110

Other funds holding KLRS

Verdad Advisers's KLRS Position: Q3 2026 in Review

Verdad Advisers increased its Kalaris Therapeutics (KLRS) stake by 75% in Q3 2026, buying an estimated $232K and bringing the position to 140,232 shares worth $405K. The position accounts for 0.43% of the portfolio, ranked #84.

Verdad Advisers first reported a position in KLRS in Q2 2026 and has held it in 2 quarters since. 54 funds tracked by Wall St. Rank hold KLRS as of Q3 2026.

  • Verdad Advisers held 140,232 shares of Kalaris Therapeutics worth $405K as of Q3 2026.
  • Verdad Advisers bought 59,935 Kalaris Therapeutics shares in Q3 2026, an estimated $232K.
  • Kalaris Therapeutics made up 0.43% of Verdad Advisers's portfolio in Q3 2026, its #84 holding.
  • Verdad Advisers first reported a position in Kalaris Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 54 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2026.

Based on Verdad Advisers's 13F filing for Q3 2026, filed 16 Nov 2026.